Charles River Laboratories (CRL)

Overall impact
B (69)

Commentary

Charles River Laboratories is a strong overall performer. With a 'B' rating of 68.7 for overall impact (79th percentile compared to all companies), Charles River Laboratories ranks 23rd out of 50 industry peers, behind Agilent, LGC Group, Pace Analytical Services and 19 others, and ahead of Eversana, SPT Labtech, Maravai LifeSciences and 24 others. On top material causes for Charles River Laboratories's industry (Life Sciences Tools & Services), Charles River Laboratories performs well in Child and Maternal Health (95.0 score), Access to Affordable Healthcare (95.3), Reduced Waste (80.3) and 10 other causes where it received an 'A' score and performs poorly in Accountable Institutions (38.2 score), Accountable Institutions (39.9), Reduced Use of tobacco (11.4) and 10 other causes where it received a 'D' or 'F' score.
Screens
Fur
Impact
Cause CRL
Peer rank
Overall impact

Log in to view this information

Screens
Fur
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
18,300
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Life Sciences Tools & Services
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ma, United States
Share classes
CRL
Mission
Together, we create healthier lives.
Description
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Material causes
Ethos considers the following causes material for Charles River Laboratories, based on its industry sub-industry Life Sciences Tools & Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.